{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-031957","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.088936+00:00","generated_at":"2026-05-30T10:31:54.294625+00:00","sec_items":["1.01","2.01","2.03","3.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Monopar acquires exclusive worldwide license for ALXN-1840 from Alexion; pays $4M cash + equity","bullets":["Monopar gets exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate) for Wilson disease; Phase 3 trial met primary endpoint, but Alexion terminated after Phase 2 results.","Upfront: $4M cash ($1M at signing, $3M in 90 days) and 387,329 shares (9.9% beneficial ownership); anti-dilution up to 705,015 total shares.","Future milestones up to $94M plus tiered royalties (low to mid-double digit) on net sales; mid-double digit sublicensing income share until sales.","Cash was ~$6M as of Sep 30, 2024; near-term expenses <$1M for regulatory package; expects substantial doubt about going concern in upcoming 10-Q.","ALXN-1840 has Orphan Drug Designation in US and EU; Monopar plans to initiate FDA discussions; regulatory path uncertain."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-031957","json":"https://secwatch.observer/filing/0001437749-24-031957.json","markdown":"https://secwatch.observer/filing/0001437749-24-031957.md","text":"https://secwatch.observer/filing/0001437749-24-031957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924031957/0001437749-24-031957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924031957/mnpr20241021_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:31:54.294625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}